Fig. 2.

Responder analysis in Neuro-QoL Short Form Fatigue T-scores at Week 12 in RAISE. The analysis was performed using the Neuro-QoL Analysis Set, which is defined as all patients who had a non-missing Neuro-QoL Short Form Fatigue T-score at RAISE baseline. For the clinically meaningful improvement threshold of − 3.5, the OR (95% CI) versus placebo was 1.15 (0.61, 2.17) with a nominal p-value of 0.659. For the clinically meaningful worsening threshold of + 3.2, the OR (95% CI) versus placebo was 0.66 (0.27, 1.64) with a nominal p-value of 0.372. CFB change from baseline, CI confidence interval, Neuro-QoL Quality of Life in Neurological Disorders, OR odds ratio